The regulator said the buyout “would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate ...

Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...

The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq ...

Surmodics, Inc. SRDX recently provided a statement in response to the U.S. Federal Trade Commission (“FTC”) blocking the ...

The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...

Surmodics (NASDAQ:SRDX) fell 4.6% after the Federal Trade Commission filed a lawsuit to block its planned $627 million sale ...

The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...

The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.

WASHINGTON (Reuters) - The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' ...

The Federal Trade Commission announced it has sued to block GTCR BC Holdings’ acquisition of Surmodics (SRDX), alleging that the deal, which ...

Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.

Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...